Breast cancer and fertility

Ronn, Ruth; Holzer, Hananel

doi:10.1097/spc.0000000000000164

Cited by 8 publications

(5 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…23 Furthermore, in 70% of the J&F cases, the strategy involved oocyte/embryo cryopreservation, the first-line options for FP in patients with cancer. 8,11,24 This proportion may be explained by the coverage of cryopreservation procedures through a dedicated governmental fund at one of the J&F sites, as well as the alliances that the program fosters with 4 assistedreproduction centers in Mexico that facilitate referral and provide special discounts for underserved patients who cannot cover these measures' total costs. It should also be noted that only 41% of the patients who preserved fertility received GnRHa.…”

Section: Discussionmentioning

confidence: 99%

Prospective Study of Fertility Preservation in Young Women With Breast Cancer in Mexico

Villarreal‐Garza

Mesa-Chavez

Mora³

et al. 2021

Journal of the National Comprehensive Cancer Network

View full text Add to dashboard Cite

Background: Despite the risk of treatment-related infertility, implementation of fertility-preservation (FP) strategies among young patients with breast cancer is often suboptimal in resource-constrained settings such as Mexico. The “Joven & Fuerte: Program for Young Women With Breast Cancer” strives to enhance patient access to supportive care services, including FP measures through alliances with assisted-reproduction units and procurement of coverage of some of these strategies. This study describes patients from Joven & Fuerte who have preserved fertility, and assesses which characteristics were associated with the likelihood of undergoing FP. Methods: Women aged ≤40 years with recently diagnosed breast cancer were prospectively accrued. Sociodemographic and clinicopathologic data were collected from patient-reported and provider-recorded information at diagnosis and 1-year follow-up. Descriptive statistics, chi-square test, and simple logistic regression were used to compare patients who preserved fertility with those who did not. Results: In total, 447 patients were included, among which 53 (12%) preserved fertility, representing 38% of the 140 women who desired future biologic children. Oocyte/embryo cryopreservation was the most frequently used method for FP (59%), followed by temporary ovarian suppression with gonadotropin-releasing hormone agonists (GnRHa) during chemotherapy (26%), and use of both GnRHa and oocyte/embryo cryopreservation (15%). Younger age, higher educational level, being employed, having private healthcare insurance, and having one or no children were associated with a significantly higher likelihood of preserving fertility. Conclusions: By facilitating referral and seeking funds and special discounts for underserved patients, supportive care programs for young women with breast cancer can play a crucial role on enhancing access to oncofertility services that would otherwise be prohibitive because of their high costs, particularly in resource-constrained settings. For these efforts to be successful and widely applied in the long term, sustained and extended governmental coverage of FP options for this young group is warranted.

show abstract

Section: Discussionmentioning

confidence: 99%

Prospective Study of Fertility Preservation in Young Women With Breast Cancer in Mexico

Villarreal‐Garza

Mesa-Chavez

Mora³

et al. 2021

Journal of the National Comprehensive Cancer Network

View full text Add to dashboard Cite

show abstract

“…Die Fortschritte in der Reproduktionsmedizin (= ART) haben zu einem Umdenken beim Fertilitätserhalt vor einer Chemotherapie geführt. Derzeit sind die Kryokonservierungen von befruchteten Eizellen und reifen Eizellen etablierte Verfahren, während die Kryokonservierung unreifer Oozyten noch als experimentell angesehen werden muss [48,49]. Die Kryokonservierung von Ovarialgewebe stellt ein weiteres Verfahren zum Fertilitätserhalt dar [17,50].…”

Section: Andere Möglichkeiten Zum Fertilitätserhaltunclassified

Erhalt der Fertilität bzw. Ovarialfunktion beim Mammakarzinom sowie bei gynäkologischen und internistischen Malignomen

Stachs¹,

Hartmann²,

Gerber³

2018

TumorDiagn u Ther

View full text Add to dashboard Cite

ZusammenfassungNeoplasien des Kindes- und Jugendalters sowie junger Erwachsener gehen heute dank effektiver Systemtherapien mit einer hohen Heilungschance einher. Demzufolge rückt das Thema „Kinderwunsch“ insbesondere bei jungen Frauen mit Malignom zunehmend in den Vordergrund. Ein nicht unwesentliches Problem ist auch die vorzeitige Ovarialinsuffizienz mit ihren die Lebensqualität nachhaltig beeinträchtigenden Folgen. Jede(r) onkologische Patient(in) mit potenziellem Kinderwunsch sollte vor Therapiebeginn über die Möglichkeiten des Fertilitätserhalts informiert werden. Die Aufklärungsrate ist diesbezüglich nach wie vor gering. In dieser Übersichtsarbeit wird der Effekt verschiedener Chemotherapeutika auf die Gonadenfunktion dargestellt sowie ein Überblick über die aktuell gültigen Empfehlungen zum Fertilitätserhalt gegeben.Dabei werden Risikokollektive definiert und das spezifische Vorgehen bei Malignomen der verschiedenen Organsysteme beschrieben. Bei Mädchen/jungen Frauen ist die Kryokonservierung von Eizellen, befruchteten Embryonen und Ovargewebe möglich. Zum Nutzen der GnRH-Analoga-Applikation zum Ovarschutz vor Chemotherapie ist die Studienlage uneinheitlich. Bei postpubertären Jungen bzw. männlichen Krebspatienten ist die Kryokonservierung von Spermien vor Therapiebeginn Standard. Bei Jungen im vorpubertären Alter ist die Kryokonservierung von Hodengewebe möglich, jedoch ist die In-vitro-Spermienreifung noch im experimentellen Stadium. Des Weiteren werden in der vorliegenden Arbeit medikamentöse Möglichkeiten des Erhalts der Ovarfunktion bei onkologischen Patienten vor Chemotherapien, insbesondere bei (hormonabhängigem) Mammakarzinom, sowie die speziellen Fragestellungen der Planung von fertilitätserhaltender Operation und Radiatio bei gynäkologischen Malignomen, dargestellt.

show abstract

“…Advances in reproductive medicine (ART) have led to a change in thinking about fertility preservation prior to chemotherapy. At present, cryopreservation of fertilized oocytes and mature oocytes is a well-established procedure, while the cryopreservation of immature oocytes is still considered to be in its experimental stages [48,49]. Cryopreservation of ovarian tissue is another procedure for preserving fertility [17,50].…”

Section: Other Options For Fertility Preservationmentioning

confidence: 99%

Preservation of Fertility or Ovarian Function in Patients with Breast Cancer or Gynecologic and Internal Malignancies

Stachs¹,

Hartmann²,

Gerber³

2017

Geburtshilfe Frauenheilkd

View full text Add to dashboard Cite

Because of the efficacy of systemic therapies, neoplasias which occur in pediatric and adolescent patients and in young adults have high cure rates. This means that fulfilling their wish to have children has become a more pressing concern, particularly among young women with malignant tumors. Premature ovarian failure is also a not insignificant problem as it has a lasting detrimental effect on quality of life. Every oncology patient who may potentially wish to have children should be informed about their options for preserving fertility prior to starting treatment. The rates of patient who received detailed briefing on this point remain low. This review presents the effects of different chemotherapeutic drugs on gonadal function together with an overview of currently valid recommendations on fertility preservation. Risk groups are defined and the specific approaches for malignancies of various organ systems are described. Cryopreservation of oocytes, fertilized embryos and ovarian tissue are fertility-preserving options for girls/young women. The data on the benefits of administering GnRH analogs for ovarian protection prior to starting chemotherapy are not clear. In postpubertal boys or male cancer patients, the standard approach is to cryopreserve sperm before starting therapy. The cryopreservation of testicular tissue is possible for prepubertal boys, however in-vitro sperm maturation is still in its experimental stages. This review also presents existing drug options for the preservation of ovarian function in oncology patients prior to chemotherapy, particularly for patients with (hormone-sensitive) breast cancer, and looks at the special issues of fertility-preserving surgery and radiation therapy in patients with gynecologic malignancies.

show abstract

Breast cancer and fertility

Abstract: The fertility impact of breast cancer treatment in young women is of ongoing concern. The effects should be universally addressed and options should be outlined with young women prior to commencement of treatment.

Cited by 8 publications

References 71 publications

Prospective Study of Fertility Preservation in Young Women With Breast Cancer in Mexico

Prospective Study of Fertility Preservation in Young Women With Breast Cancer in Mexico

Erhalt der Fertilität bzw. Ovarialfunktion beim Mammakarzinom sowie bei gynäkologischen und internistischen Malignomen

Preservation of Fertility or Ovarian Function in Patients with Breast Cancer or Gynecologic and Internal Malignancies

Contact Info

Product

Resources

About